Engineered “organoids” function like real kidneys when implanted into rats
• From suspensions of single kidney cells, researchers have constructed “organoids” that can carry out kidney functions when implanted into a living animal.
• The advance marks a considerable step toward the goal of engineering kidney tissues suitable for transplantation.
Tissue engineering of kidneys could help alleviate the shortage of kidneys for transplantation.
Newswise — Washington, DC (October 18, 2012) — With a worldwide shortage of kidneys for patients who need kidney transplants, researchers are diligently working to find ways to engineer new kidney tissue from a patient’s own cells or another source. They’ve come a step closer to realizing that goal with a breakthrough described in an upcoming Journal of the American Society of Nephrology (JASN) study. The advance could lead to more options for individuals with kidney failure, as well as better tools for understanding kidney diseases and how to treat them.
Investigators can produce tissues similar to immature kidneys from simple suspensions of embryonic kidney cells, but they have been unsuccessful at growing more mature kidney tissues in the lab because the kidneys’ complicated filtering units do not form without the support of blood vessels.
Now, from suspensions of single kidney cells, Christodoulos Xinaris PhD (Mario Negri Institute for Pharmacological Research) and his colleagues have for the first time constructed “organoids” that can be integrated into a living animal and carry out kidney functions including blood filtering and molecule reabsorption. Key to their success was soaking the organoids in a solution containing molecules that promote blood vessel formation, then injecting these molecules into the recipient animals after the organoids were implanted below the kidneys. The organoids continued to mature and were viable for three to four weeks after implantation.
“The ability to build functional renal tissue starting from suspensions of single cells represents a considerable step toward the practical goal of engineering renal tissues suitable for transplantation and offers the methodological basis for a number of investigative and therapeutic applications,” said Dr. Xinaris. For example, disease-related genes could be introduced into an organoid to help researchers study the mechanisms of complex kidney diseases and to perform a preliminary screening of new drugs to treat them.
Study co-authors include Valentina Benedetti, BiolSciD, Paola Rizzo, BiolSciD, Mauro Abbate, MD, Daniela Corna, Nadia Azzolini, Sara Conti, BSc, Mathieu Unbekand, PhD, Jamie A. Davies, PhD, Marina Morigi PhD, Ariela Benigni, PhD, and Giuseppe Remuzzi, MD.
Disclosures: The authors reported no financial disclosures.
The article, entitled “In Vivo Maturation of Functional Renal Organoids Formed from Embryonic Cell Suspensions,” will appear online at http://jasn.asnjournals.org/ on October 18, 2012, doi: 10.1681/ASN.2012050505.
The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.
Founded in 1966, and with more than 13,500 members, the American Society of Nephrology (ASN) leads the fight against kidney disease by educating health professionals, sharing new knowledge, advancing research, and advocating the highest quality care for patients.
# # #